Business
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned – LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today a
About this update from Immix Biopharma, Inc.
[{"type":"image","alt":"Immix Biopharma, Inc.","displaySize":"","headline":null,"caption":"Immix Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/2c6c1d83bafb554be7762f3727be359d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wOmQhF0jrEFCj3SbuTNPPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2c6c1d83bafb554be7762f3727be359d","width":300,"height":93}},"lazy":false},{"type":"text","content":"– Absence of neurotoxicity of any grade in low-volume disease to-date –","length":71,"tagName":"p"},{"type":"text","content":"– On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis –","length":136,"tagName":"p"},{"type":"text","content":" – Potential future indication expansion planned –","length":49,"tagName":"p"},{"type":"text","content":"LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced a class-leading safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any grade in low-volume disease to-date, laying a foundation for potential future indication expansion.","length":462,"tagName":"p"},{"type":"text","content":"“We are singularly focused on completing NEXICART-2 for BLA submission, where we are accelerating progress. Separately and subsequently, for potential future expansion directions, we believe NXC-201 will be able to address a range of immune-mediated and other serious diseases,” said Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Our near-term efforts are laser- focused on our path to NEXICART-2 BLA submission for FDA approval.”","length":523,"tagName":"p"},{"type":"text","content":"NEXICART-2 interim results, including safety results, were presented at the American Society for Clinical Oncology (ASCO 2025) by Heather Landau, MD of Memorial Sloan Kettering Cancer Center can be accessed on the Company’s website under publications (ASCO Post article and video, MSKCC article, Cleveland Clinic artic...